NVAX - Novavax Inc Stock Price, Fair Value and News

$13.61+1.69 (+14.18%)

Delayed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

NVAX RSI Chart

NVAX Valuation

Market Cap

2.2B

Price/Earnings (Trailing)

-7.4

Price/Sales (Trailing)

2.21

EV/EBITDA

-6.54

Price/Free Cashflow

152.96

NVAX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

NVAX Fundamentals

NVAX Revenue

Revenue (TTM)

987.7M

Rev. Growth (Yr)

-2.11%

Rev. Growth (Qtr)

342.69%

NVAX Earnings

Earnings (TTM)

-294.3M

Earnings Growth (Yr)

179.93%

Earnings Growth (Qtr)

210.05%

NVAX Price Action

Last 7 days

17.0%

Last 30 days

11.7%

Last 90 days

-5.5%

Trailing 12 Months

70.3%

NVAX Profitability

Operating Margin

63.62%

EBT Margin

-29.25%

Return on Equity

68.18%

Return on Assets

-16.18%

Free Cashflow Yield

0.65%

NVAX Financial Health

Current Ratio

1.04

NVAX Investor Care

Shares Dilution (1Y)

69.58%

Diluted EPS (TTM)

-2.71

NVAX Alerts

Big jump in Earnings (Y/Y)

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	996.6M	987.7M	0	0
2023	1.4B	1.6B	1.0B	983.7M
2022	1.4B	1.3B	1.8B	2.0B
2021	919.5M	1.2B	1.2B	1.1B
2020	18.1M	50.2M	204.8M	475.6M
2019	28.6M	21.2M	16.0M	18.7M
2018	35.1M	39.2M	38.6M	34.3M
2017	16.8M	21.0M	26.2M	31.2M
2016	30.6M	19.1M	15.8M	15.4M
2015	33.1M	38.8M	37.1M	36.3M
2014	24.5M	29.3M	32.7M	30.7M
2013	21.3M	17.7M	16.7M	20.9M
2012	18.5M	22.6M	23.4M	22.1M
2011	2.2M	4.1M	8.9M	14.7M
2010	0	331.0K	337.0K	343.0K
2009	0	0	0	325.0K

Get all data in R, Python etc through our Historical Stock Data APIs

About Novavax Inc

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 and influenza combined. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, Adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also focusing on products candidates for respiratory syncytial virus and malaria. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

CEO	Mr. John Charles Jacobs M.B.A.
WEBSITE	novavax.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	1992

Novavax Inc Frequently Asked Questions

What is the ticker symbol for Novavax Inc? What does NVAX stand for in stocks?

NVAX is the stock ticker symbol of Novavax Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Novavax Inc (NVAX)?

As of Fri Sep 13 2024, market cap of Novavax Inc is 2.18 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of NVAX stock?

You can check NVAX's fair value in chart for subscribers.

Is Novavax Inc a good stock to buy?

The fair value guage provides a quick view whether NVAX is over valued or under valued. Whether Novavax Inc is cheap or expensive depends on the assumptions which impact Novavax Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for NVAX.

What is Novavax Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Sep 13 2024, NVAX's PE ratio (Price to Earnings) is -7.4 and Price to Sales (PS) ratio is 2.21. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. NVAX PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Novavax Inc's stock?

In the past 10 years, Novavax Inc has provided -0.172 (multiply by 100 for percentage) rate of return.